Skip to main content

Table 1 The clinicopathologic characteristics of AJAP1 expression in 283 Breast cancer patients

From: β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer

Parameters

Cases

AJAP1

p

Low expression (N, %)

High expression (N, %)

Age(yr)

 

118(41.7)

165(58.3)

 

 ≤50

130

49(41.5)

81(49.1)

0.208

 > 50

153

69(58,5)

84(50.9)

 

Menopausal status

 Premenopausal

156

60(50.8)

96(58.2)

0.221

 Postmenopausal

127

58(49.2)

69(41.8)

 

Family history

 No

194

85(72.0)

109(66.1)

0.286

 Yes

89

33(28.0)

56(33.9)

 

Tumor size

 T1

103

42(35.6)

68(41.2)

0.615

 T2

148

66(55.9)

83(50.3)

 

 T3

32

10(8.5)

14(8.5))

 

Histological grade

 1

44

9(7.6)

35(21.2)

< 0.0001*

 2

153

59(50.0)

94(57.0)

 

 3

86

50(42.4)

36(21.8)

 

LN involvement

 0

180

65(55.1)

115(69.7)

0.010*

 1–3

43

19(16.1)

24(14.5)

 

 4–9

41

20(16.9)

21(12.7)

 

  ≥ 10

19

14(11.9)

5(3.0)

 

ER

 Negative

111

50(42.4)

61(37)

0.359

 Positive

172

68(57.6)

104(63)

 

PR

 Negative

142

83(41.5)

82(49.7)

0.849

 Positive

141

35(42.2)

83(50.3)

 

Her-2

 Negative

200

83(41.5)

117(58.5)

0.917

 Positive

83

35(42.2)

48(57.8)

 

Ki67

  < 20

83

31(26.3)

52(31.5)

0.339

  ≥ 20

200

87(73.7)

113(68.5)

 

P53

 Negative

143

59(50)

84(50.9)

0.880

 Positive

140

59(50)

81(49.1)

 
  1. *significantly different